Tesofensina

Tesofensine is a triple-monoamine reuptake inhibitor originally developed for neurodegenerative disorders but repurposed for obesity treatment. Clinical pharmacokinetics show an elimination half-life of ≈220 hours with an active N-desalkyl metabolite (NS2360) lasting ≈374 hours; steady-state is reached only after 4-5 weeks. Single overdoses can linger for over a week. Community reports emphasize starting at ≤0.25 mg every 48 hours to limit insomnia, anxiety, and heart rate increases (8-15 bpm above baseline). Research chemical vendor authenticity varies; reagent testing with TLC plus chiral GC-MS is advised.

Also known as: Te, Ns-2330

Classification

Chemical: Tropane
Psychoactive: Stimulant
Tag: Appetite-suppressant
Tag: Phenyltropane
Tag: Research-Chemical

Effects

Mental Stimulation
Dry Mouth
Insomnia
Tachycardia
Diarrhea
Nausea
Motivation Enhancement
Focus Enhancement
Anxiety
Talkativeness
Alertness Enhancement
Thought Acceleration
Appetite Suppression
Light Sensitivity
Increased Libido
Disinhibition
Dehydration
Tactile Enhancement

Routes of Administration

Oral

Dosage

Threshold: 0.05 mg
Light: 0.05-0.20 mg
Common: 0.20-0.50 mg
Strong: 0.50-1 mg
Heavy: 1 mg

Duration

Onset: 0.5-2 h
Comeup: 2-4 h
Peak: 4-10 h
Offset: 12-24 h
After Effects: 24-72 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

dose.wiki

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu